South Africa’s New COVID-19 Antigen Test is Able to Detect Omicron 12/01/2022 Kerry Cullinan CAPE TOWN – A locally produced COVID-19 rapid antigen test that was recently approved by South Africa’s medicines regulator is able to detect Omicron, according to its developer. This follows some controversy about whether antigen tests were able to detect Omicron, and suggestions that throat swabs might be more effective than nasal swabs as Omicron […] Continue reading -> COVID-19 Vaccination Has Slight But ‘Clinically Insignificant’ Impact on Menstruation 07/01/2022 Maayan Hoffman Women who have been vaccinated against COVID-19 had a slight but not clinically significant change in the length of their menstrual cycles compared to unvaccinated women, according to a new study published by researchers from Oregon Health & Science University in Portland in Obstetrics & Gynecology. Specifically, vaccinated women experienced a less than one-day (0.71-day) […] Continue reading -> Gloomy New Year Prognosis – WHO Experts Warn Omicron Could Also Spawn More Dangerous Variants 06/01/2022 Maayan Hoffman Mass Omicron infection could lead to the formation of new and potentially even more dangerous coronavirus variants, officials from the World Health Organization warned on Thursday. That is despite the fact that the Omicron variant is proving less lethal than its SARS-CoV2 predecessors, such as Alpha, Beta and Delta – which swept through India and […] Continue reading -> Israel Finds Fourth Pfizer Dose Produces Five-fold Increase in Antibodies, as Country Prepares to Launch Moderna Fourth Shot Trial 04/01/2022 Maayan Hoffman A fourth shot of the Pfizer coronavirus vaccine administered to individuals who received their third shot nearly five months ago produces a five-fold increase in antibodies, according to preliminary results of a first-in-the-world trial being conducted in Israel. The news comes on the same day that the country announced it would launch a trial to […] Continue reading -> As Europe Sees Wave of Seasonal Flu – What are the Risks for ‘Flurona?’ 04/01/2022 Maayan Hoffman The world’s first case of “flurona” – a co-infection with both seasonal influenza and COVID-19 was reported in Israel last week, as the Omicron variant sweeps across the world. Since then, small numbers of people co-infected with both viruses have been identified in other European countries as well, a World Health Organization official in the […] Continue reading -> Second J& J Jab Provides 85% Protection Against Omicron Hospitalization in New South African Study 30/12/2021 Elaine Ruth Fletcher A new South African study shows that a second Johnson & Johnson dose, administered 6-9 months after the initial single-dose vaccine provided 84% protection against hospitalization from the Omicron SARS-CoV2 variant – results that even outperformed those of an earlier South African study looking at effectiveness of the two-dose Pfizer regime in the face of […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Posts navigation Older postsNewer posts
COVID-19 Vaccination Has Slight But ‘Clinically Insignificant’ Impact on Menstruation 07/01/2022 Maayan Hoffman Women who have been vaccinated against COVID-19 had a slight but not clinically significant change in the length of their menstrual cycles compared to unvaccinated women, according to a new study published by researchers from Oregon Health & Science University in Portland in Obstetrics & Gynecology. Specifically, vaccinated women experienced a less than one-day (0.71-day) […] Continue reading -> Gloomy New Year Prognosis – WHO Experts Warn Omicron Could Also Spawn More Dangerous Variants 06/01/2022 Maayan Hoffman Mass Omicron infection could lead to the formation of new and potentially even more dangerous coronavirus variants, officials from the World Health Organization warned on Thursday. That is despite the fact that the Omicron variant is proving less lethal than its SARS-CoV2 predecessors, such as Alpha, Beta and Delta – which swept through India and […] Continue reading -> Israel Finds Fourth Pfizer Dose Produces Five-fold Increase in Antibodies, as Country Prepares to Launch Moderna Fourth Shot Trial 04/01/2022 Maayan Hoffman A fourth shot of the Pfizer coronavirus vaccine administered to individuals who received their third shot nearly five months ago produces a five-fold increase in antibodies, according to preliminary results of a first-in-the-world trial being conducted in Israel. The news comes on the same day that the country announced it would launch a trial to […] Continue reading -> As Europe Sees Wave of Seasonal Flu – What are the Risks for ‘Flurona?’ 04/01/2022 Maayan Hoffman The world’s first case of “flurona” – a co-infection with both seasonal influenza and COVID-19 was reported in Israel last week, as the Omicron variant sweeps across the world. Since then, small numbers of people co-infected with both viruses have been identified in other European countries as well, a World Health Organization official in the […] Continue reading -> Second J& J Jab Provides 85% Protection Against Omicron Hospitalization in New South African Study 30/12/2021 Elaine Ruth Fletcher A new South African study shows that a second Johnson & Johnson dose, administered 6-9 months after the initial single-dose vaccine provided 84% protection against hospitalization from the Omicron SARS-CoV2 variant – results that even outperformed those of an earlier South African study looking at effectiveness of the two-dose Pfizer regime in the face of […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Posts navigation Older postsNewer posts
Gloomy New Year Prognosis – WHO Experts Warn Omicron Could Also Spawn More Dangerous Variants 06/01/2022 Maayan Hoffman Mass Omicron infection could lead to the formation of new and potentially even more dangerous coronavirus variants, officials from the World Health Organization warned on Thursday. That is despite the fact that the Omicron variant is proving less lethal than its SARS-CoV2 predecessors, such as Alpha, Beta and Delta – which swept through India and […] Continue reading -> Israel Finds Fourth Pfizer Dose Produces Five-fold Increase in Antibodies, as Country Prepares to Launch Moderna Fourth Shot Trial 04/01/2022 Maayan Hoffman A fourth shot of the Pfizer coronavirus vaccine administered to individuals who received their third shot nearly five months ago produces a five-fold increase in antibodies, according to preliminary results of a first-in-the-world trial being conducted in Israel. The news comes on the same day that the country announced it would launch a trial to […] Continue reading -> As Europe Sees Wave of Seasonal Flu – What are the Risks for ‘Flurona?’ 04/01/2022 Maayan Hoffman The world’s first case of “flurona” – a co-infection with both seasonal influenza and COVID-19 was reported in Israel last week, as the Omicron variant sweeps across the world. Since then, small numbers of people co-infected with both viruses have been identified in other European countries as well, a World Health Organization official in the […] Continue reading -> Second J& J Jab Provides 85% Protection Against Omicron Hospitalization in New South African Study 30/12/2021 Elaine Ruth Fletcher A new South African study shows that a second Johnson & Johnson dose, administered 6-9 months after the initial single-dose vaccine provided 84% protection against hospitalization from the Omicron SARS-CoV2 variant – results that even outperformed those of an earlier South African study looking at effectiveness of the two-dose Pfizer regime in the face of […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Posts navigation Older postsNewer posts
Israel Finds Fourth Pfizer Dose Produces Five-fold Increase in Antibodies, as Country Prepares to Launch Moderna Fourth Shot Trial 04/01/2022 Maayan Hoffman A fourth shot of the Pfizer coronavirus vaccine administered to individuals who received their third shot nearly five months ago produces a five-fold increase in antibodies, according to preliminary results of a first-in-the-world trial being conducted in Israel. The news comes on the same day that the country announced it would launch a trial to […] Continue reading -> As Europe Sees Wave of Seasonal Flu – What are the Risks for ‘Flurona?’ 04/01/2022 Maayan Hoffman The world’s first case of “flurona” – a co-infection with both seasonal influenza and COVID-19 was reported in Israel last week, as the Omicron variant sweeps across the world. Since then, small numbers of people co-infected with both viruses have been identified in other European countries as well, a World Health Organization official in the […] Continue reading -> Second J& J Jab Provides 85% Protection Against Omicron Hospitalization in New South African Study 30/12/2021 Elaine Ruth Fletcher A new South African study shows that a second Johnson & Johnson dose, administered 6-9 months after the initial single-dose vaccine provided 84% protection against hospitalization from the Omicron SARS-CoV2 variant – results that even outperformed those of an earlier South African study looking at effectiveness of the two-dose Pfizer regime in the face of […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Posts navigation Older postsNewer posts
As Europe Sees Wave of Seasonal Flu – What are the Risks for ‘Flurona?’ 04/01/2022 Maayan Hoffman The world’s first case of “flurona” – a co-infection with both seasonal influenza and COVID-19 was reported in Israel last week, as the Omicron variant sweeps across the world. Since then, small numbers of people co-infected with both viruses have been identified in other European countries as well, a World Health Organization official in the […] Continue reading -> Second J& J Jab Provides 85% Protection Against Omicron Hospitalization in New South African Study 30/12/2021 Elaine Ruth Fletcher A new South African study shows that a second Johnson & Johnson dose, administered 6-9 months after the initial single-dose vaccine provided 84% protection against hospitalization from the Omicron SARS-CoV2 variant – results that even outperformed those of an earlier South African study looking at effectiveness of the two-dose Pfizer regime in the face of […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Posts navigation Older postsNewer posts
Second J& J Jab Provides 85% Protection Against Omicron Hospitalization in New South African Study 30/12/2021 Elaine Ruth Fletcher A new South African study shows that a second Johnson & Johnson dose, administered 6-9 months after the initial single-dose vaccine provided 84% protection against hospitalization from the Omicron SARS-CoV2 variant – results that even outperformed those of an earlier South African study looking at effectiveness of the two-dose Pfizer regime in the face of […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Posts navigation Older postsNewer posts
‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Posts navigation Older postsNewer posts
The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Posts navigation Older postsNewer posts
US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Posts navigation Older postsNewer posts
Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Posts navigation Older postsNewer posts